Alexander Hardy; President, Chief Executive Officer, Director; Biomarin Pharmaceutical Inc Brian Mueller; Chief Financial Officer, Executive Vice President; Biomarin Pharmaceutical Inc Cristin ...

A slimmed-down BioMarin started the new year with a bang, hitting the annual J.P. Morgan Healthcare Conference with the goal of tapping its skillset to strike deals that bolster its pipeline of ...

On Wednesday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ago, beating the consensus of 53 cents. The company ...

BioMarin Pharmaceutical has a 1 year low of $60.63 and a 1 year high of $94.85. The company has a market capitalization of $13.45 billion, a P/E ratio of 32.05, a P/E/G ratio of 0.61 and a beta of ...

BioMarin Pharmaceutical (NASDAQ:BMRN), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped ...

BioMarin is amassing a portfolio of genetic-disease therapeutics, making historical comparisons with Genzyme (acquired by Sanofi) difficult to avoid. Commercialization and research and development ...

BioMarin Pharmaceutical Stock Up 0.1 % BMRN opened at $70.60 on Friday. The firm has a 50 day moving average price of $66.16 and a 200 day moving average price of $69.10. The company has a market ...

Both headline numbers obliterated analyst estimates. Collectively, pundits tracking BioMarin's stock were estimating the company would earn a bit over $711 million and post an adjusted net income ...

SAN RAFAEL, Calif. (AP) — SAN RAFAEL, Calif. (AP) — BioMarin Pharmaceutical Inc. (BMRN) on Wednesday reported fourth-quarter profit of $124.9 million. The San Rafael, California-based company ...

BioMarin Pharmaceutical BMRN is scheduled to report fourth-quarter and full-year 2024 earnings on Feb. 19, after market close. In the last reported quarter, BMRN’s earnings beat estimates by 16. ...